Role of carbohydrate antigen 19-9, carcinoembryonic antigen, and carbohydrate antigen 125 as the predictors of resectability and survival in the patients of Carcinoma Gall Bladder

Abstract

INTRODUCTION: Carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) have been reported in previous studies to assess the prognosis of gall bladder cancer (GBC) individually and in combination. However, the evidence of utility of preoperative CA 19-9, CEA and carbohydrate antigen 125 (CA 125) in determining the resectability and prognosis of GBC is still lacking. In the present study we correlated the serum levels of tumor markers CA 19-9, CEA and CA 125 individually and combined to determine the resectability and prognosis of the GBC. MATERIALS AND METHODS: Seventy one diagnosed patients of GBC between January 2018 and September 2019 were included in the present study. Serum CA 19-9, CEA and CA 125 were determined by chemiluminescence. Receiver operating characteristic (ROC) curve was used to evaluate the role of tumor markers in determining the resectability of GBC. The Kaplan Meier survival curves were made and log rank analysis was performed to assess the prognostic role of tumor markers in terms of overall median survival. RESULTS: All the three tumor markers CA19-9, CEA and CA 125 showed high discriminatory power in determining the resectability with respective area under curve of 0.76, 0.68 and 0.78 as determined by ROC. Median survival in patients with high serum CA 19-9, CA 125 was significantly lower than patients with normal serum CA 19-9, CA 125 whereas no significant difference was observed in case of CEA. CONCLUSION: The present study suggested that CA 19-9, CEA and CA 125 can predict resectability in GBC and raised levels of CA 19-9 and CA 125 can predict poor prognosis in patients with elevated levels.

Noninvasive preoperative differential diagnosis of gallbladder carcinoma and xanthogranulomatous cholecystitis: A retrospective cohort study of 240 patients

“…However, CEA was the only tumor marker that showed a significant difference between GBC and XGC patients (higher in XGC patients). Although it was reported that CA19‐9 concentration is superior to CEA in judging the necessity of surgical removal of advanced gallbladder cancer, 16 as well as in prediction of disease progression of GBC patients, 17 , 18 our result showed that CEA showed an advantage in differentiating GBC and XGC. Thus, CEA presented potential in differentiating XGC and GBC.…”

The role of GPLD1 in chronic diseases

“…Carcinoembryonic antigen (CEA) is one of the most extensively used clinical tumor markers (Agrawal et al, 2020; Farahani et al, 2020; Grunnet & Sorensen, 2012; Sidorina et al, 2021), which is upregulated in advanced colorectal cancer by approximately 90% (Yamamoto et al, 2005). CEA is attached to the surface of cell membrane via GPI anchor, thus the membrane‐bound CEA can be cleaved by GPLD1 (Bramswig et al, 2013).…”